Peel Therapeutics, Inc.

Unlocking evolutionary biology to treat patients with cancer and inflammatory diseases.

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Dr. Filemon Dela Cruz, a pediatric hematologist-oncologist at MSK, shared his poster on “Preclinical evaluation of PEG-[SN22]₄ (PEEL-224), a multivalent polymeric camptothecin prodrug, in pediatric solid tumor patient-derived xenograft models” during #AACR26. @aacr

[Peel Therapeutics, Inc. @peel_tx]

One more day to vote! Polling closes on Tuesday night. Let the Cancer Fund know what you think about Peel's medicine to beat pancreatic cancer: https://t.co/6uyTcAvMRq

[Peel Therapeutics, Inc. @peel_tx]

Peel Therapeutics is proud to support the @ElephantsIEF. We began our company with the recognition that elephants are naturally cancer resistant. We must continue to protect and learn from these amazing creatures! 🐘🐘🐘🐘

https://t.co/jIkGz5KNfB

[IntlElephantFoundatn @ElephantsIEF]

Because elephants are amazing, they bring amazing people together; IEF is proud for the support and collaboration with scientists at Peel Therapeutics @peel_tx. Science and conservation go hand in trunk! Our shared commitment to helping elephants (and people!) is highlighted in our latest Conservation Chat with Drs. Joshua Schiffman & Lisa Abegglen. Watch the replay here:
https://t.co/7gpnYdDlan
#ConservationChat #TheMoreYouKnow

[IntlElephantFoundatn @ElephantsIEF]

Because elephants are amazing, they bring amazing people together; IEF is proud for the support and collaboration with scientists at Peel Therapeutics @peel_tx. Science and conservation go hand in trunk! Our shared commitment to helping elephants (and people!) is highlighted in our latest Conservation Chat with Drs. Joshua Schiffman & Lisa Abegglen. Watch the replay here:
https://t.co/7gpnYdDlan
#ConservationChat #TheMoreYouKnow

[Peel Therapeutics, Inc. @peel_tx]

https://t.co/KuATnQc3uz

[Peel Therapeutics, Inc. @peel_tx]

https://t.co/Bm21FC70O1

[Peel Therapeutics, Inc. @peel_tx]

https://t.co/Bm21FC70O1

[Good Medicine Podcast @GoodMedicinePod]

Our first guest is a rock star. Don't miss it.

[Good Medicine Podcast @GoodMedicinePod]

Our first guest is a rock star. Don't miss it.

[Peel Therapeutics, Inc. @peel_tx]

Looking forward to tomorrow's Good Medicine Podcast with @dave_bearss !!!

https://t.co/avYmqKdFfk

[Peel Therapeutics, Inc. @peel_tx]

Excited for Children's Hospital of Philadelphia (CHOP) and their patients who now have access to PEEL-224 through a new CHOP-sponsored clinical trial. Amazing to reach this pediatric milestone in PEEL-224 development, a drug originally developed at CHOP.

https://t.co/IsqyfCupii

[Peel Therapeutics, Inc. @peel_tx]

Excited for Children's Hospital of Philadelphia (CHOP) and their patients who now have access to PEEL-224 through a new CHOP-sponsored clinical trial. Amazing to reach this pediatric milestone in PEEL-224 development, a drug originally developed at CHOP.

https://t.co/IsqyfCupii

[Joshua Schiffman @jdschiffman]

Excited to give closing talk this afternoon at the AACR WORKSHOP ON TRANSLATIONAL CANCER RESEARCH FOR BASIC SCIENTISTS. Thank you, @AACR , for this opportunity. Go evolutionary medicine! Go Peel Therapeutics!

[Peel Therapeutics, Inc. @peel_tx]

Great new article today by @luisatorresduq in @DrugDiscovNews about our Darwin Discovery Platform in Peel Therapeutics!

https://t.co/QEY2K6n740

[Peel Therapeutics, Inc. @peel_tx]

Great new article today by @luisatorresduq in @DrugDiscovNews about our Darwin Discovery Platform in Peel Therapeutics!

https://t.co/QEY2K6n740

[Peel Therapeutics, Inc. @peel_tx]

Peel Therapeutics will present tomorrow at MEDINVEST ONCOLOGY INVESTOR CONFERENCE. We will discuss our TOP1 inhibitor engineered to improve delivery and avoid chemoresistance. Read more about Peel and our pipeline of evolutionary medicines: https://t.co/5f93CyouHb

[Peel Therapeutics, Inc. @peel_tx]

Our Peel team is presenting data this week on PEEL-224, our lead clinical asset which is a new TOP1 inhibitor engineered for better delivery and decreased chemoresistance. Come visit if you're nearby!

https://t.co/LMeOkpTrsK

[Peel Therapeutics, Inc. @peel_tx]

Great article this week in @BioWorld that describes @peel_tx and our best-in-class TOP1 inhibitor in Phase 1 clinical trial for advanced solid tumors. @peel_tx unlocks evolutionary biology to make new medicines for patients in need.
https://t.co/n4k5ORQXUm

[JTH @JTHjournal]

#September2023 selected by EIC @JHMorrissey @DavidLillicrap
NETosis induction levels by #COVID19 plasma ▶️illness severity, duration, #platelets activation & coagulation factors.
#LongCovid ▶️📈 NETosis induction.
@kmartinod @CMVB_KULeuven @KU_Leuven
https://t.co/Wq0CpEo18m

[Kim Martinod @kmartinod]

@JTHjournal @JHMorrissey @DavidLillicrap @CMVB_KULeuven @KU_Leuven An honor for this study to be highlighted in this month's issue of @JTHjournal ! This study was possible thanks to an excellent collaborative effort with @peel_tx's IL team @RambamHCC @ShaareZedekMed @AviSchroeder and Con Yost @UofUHealth
The paper is available w/Open Access🔓

[Peel Therapeutics, Inc. @peel_tx]

https://t.co/eLA5aylTmz

[Peel Therapeutics, Inc. @peel_tx]

CONGRATS to Peel Co-Founder and Board member, @AviSchroeder, on being PRESIDENT-ELECT of CONTROLLED RELEASE SOCIETY (CRS). Join Dr. Schroeder in Las Vegas this week at CRS 2023 Annual Meeting and ask him how Peel delivers evolution to patients with cancer and inflammation.